Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2014

View Archived Issues

Repurposing dopamine receptor antagonists antipsychotic for the treatment of brain cancer

TG-1042 shows clinical benefit in phase II study in cutaneous B-cell lymphoma

Guerbet and Sirtex Medical to collaborate on trials in liver cancer

Merck & Co. designs improved pan-genotypic HCV NS3/4A protease inhibitors

Scientists at RespiVert and Topivert Pharma synthesize novel protein kinase inhibitors

Cancer Research UK begins vaccine trial against cancer caused by Epstein-Barr virus

Courtagen Life Sciences to provide genetic testing in RP-103 study

Effective and safe silencing of CTGF with RXI-109 expected to inhibit skin scarring

Daiichi Sankyo outlines plans for TaNeDS program in 2014

NICE final guidance recommends MabThera for ANCA-associated vasculitis

Dimerix Bioscience raises funds to advance DMX-200

First patient enrolled in phase IIa trial of ORMD-0801 in type 1 diabetes

Alimera Sciences resubmits Iluvien NDA to FDA

Enrollment begins in phase III study of ZS-9 in patients with hyperkalemia

Xenon Pharmaceuticals and Genentech establish new pain genetics collaboration

First patient dosed in Norgine and Innovacell's phase IIb trial of ICEF-15

Pfizer achieves primary endpoint in phase IIIb study of Genotropin

Gemigliptin/metformin fixed-dose combination shows promise in healthy volunteers

Adipophilin as a potential new marker for Burkitt's lymphoma

Mast Therapeutics begins phase II study of MST-188 in acute lower limb ischemia

Genmab achieves second milestone in daratumumab collaboration with Janssen

Bristol-Myers Squibb patents new JAK inhibitors

Researchers at Plexxikon design novel agents for cancer

AbbVie discloses new NO production inhibitors

Transgene and partners outline development plan for Pexa-Vec

EMA validates ledipasvir/sofosbuvir MAA and grants accelerated assessment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...